New findings suggest that popular GLP-1 drugs, widely prescribed for weight loss and type 2 diabetes, may significantly influence a patient’s risk of developing certain cancers. This is mainly for the better. A comprehensive review of medical records has uncovered a compelling link. It found that the use of GLP-1 agonists – such as Ozempic, Wegovy, Mounjaro, and Zepbound –…
Tag: mounjaro
-
Ozempic and Mounjaro are reshaping South Africa’s health market
The landscape of weight management and diabetes treatment in South Africa is undergoing a dramatic transformation. This change is driven by the meteoric rise in popularity of a class of drugs known as GLP-1s, including Ozempic and Mounjaro. These medications, initially developed for Type 2 diabetes, have shown significant efficacy in promoting weight loss. As a result, there is unprecedented…
-
Lilly’s Orforglipron Shows Significant Weight Loss in Phase 3 Trial
Eli Lilly has announced promising results from a Phase 3 trial of its oral drug, orforglipron. The trial demonstrated significant efficacy in reducing weight and blood sugar levels in patients with type 2 diabetes. Significant Weight Loss and Blood Sugar Control with Orforglipron In the 40-week study, patients taking orforglipron lost up to 7.9% of their body weight (approximately 16…
-
As competition heats up, Novo Nordisk’s share price declines
Danish pharmaceutical giant Novo Nordisk, renowned for its diabetes and weight loss drugs Ozempic and Wegovy, has experienced a significant share price drop of around 19% this month. This decline follows its market peak in June, driven by increasing competition from Eli Lilly, a key player in the same space. Eli Lilly has gained substantial momentum with its rival drugs,…